In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Device Financings: Bad, Could be Worse

Executive Summary

The public market for device offerings isn't completely dead but the private market is looking pretty good in comparison. In fact, public companies in the last 15 months have raised more money, when private financings are taken into consideration, then the same group did in the previous 15 month period.

You may also be interested in...



Late-Stage Dealmaking Takes Off

Some VCs insist that only 25%-30% of device investments find a successful exit -- significantly better than the 10% of biotech deals, but still far from a sure thing. As a result, over the past year or so, there has been a marked increase in interest in late-stage dealmaking -- investments made at Series C or later or via alternative vehicles such as PIPE deals and SPACs.

The Sell/Go Public Dilemma for Device Companies

With device company investors worried about exit strategies, companies and their financiers are looking for creative ways to get deals done. Limited exit opportunities are making financiers anxious, driving them to put more money into fewer start-ups, which target devices aimed at larger markets. Some entrepreneurs are forming incubators to focus on niche products in which they develop new technologies, then sell them without building companies around them.

Health And Wellness Trademark Review 14 January, 2020

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

IV001167

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel